A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Strategies to enhance the immunogenicity of DNA vaccines in humans include i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in vivo electroporation (IM/EP) and/or iii) boosting with a different vaccine. Combining these strategies provided protection of macaqu...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Juliet Mpendo, Gaudensia Mutua, Julien Nyombayire, Rosine Ingabire, Annet Nanvubya, Omu Anzala, Etienne Karita, Peter Hayes, Jakub Kopycinski, Len Dally, Drew Hannaman, Michael A Egan, John H Eldridge, Kristen Syvertsen, Jennifer Lehrman, Beth Rasmussen, Jill Gilmour, Josephine H Cox, Patricia E Fast, Claudia Schmidt
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Public Library of Science (PLoS) 2015-01-01
Serie:	PLoS ONE
Accesso online:	http://europepmc.org/articles/PMC4529153?pdf=render
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Documenti analoghi